Experts from Johnson Matthey examine some of the hottest trends in drug development. With many new drugs suffering from poor solubility and bioavailability, Alan Chorlton discusses why solid state science is more important than ever before, while Paul Evans examines the innovator drugs today that will be tomorrow’s generic targets. Looking to the medicines of the future, Beatriz Dominguez and Ahir Pushpanath explain how enzyme engineering has opened up new possibilities in biocatalysis, and Kevin Hennessy looks at the growing interest in cannabinoid drug development. Finally, Nick Shackley gives his view on why outsourcing can help companies get the most from their molecules.
>> Download the PDF
Newsletters
Receive the latest pharmaceutical news, personalities, education, and career development – weekly to your inbox.
